Objective To investigate the serum level of interleukin-35 ( IL-35) and its influence on CD8+T cell function in patients with acute-on-chronic liver failure ( ACLF) . Methods A total of 28 patients with ACLF who attended Hainan Provincial People's Hospital from November 2018 to April 2019 and 14 healthy controls were enrolled in this study. ELISA was used to measure the serum level of IL-35. Peripheral CD8+T cells were separated and stimulated with recombinant human IL-35, and real-time quantitative PCR was used to measure the mRNA expression of perforin, granzyme B, and granulysin in CD8+T cells; flow cytometry was used to measure the expression of programmed death-1 ( PD-1) and cytotoxic T-lymphocyte-associated antigen 4 ( CTLA-4) in CD8+T cells. The direct-and indirect-contact co-culture systems were used for the co-culture of HLA-A2-restricted CD8+T cells and HepG2 cells, and after recombinant human IL-35 was added, the percentage of target cell death and the secretion of cytokines were measured to evaluate the changes in the cytolytic and noncytolytic activities of CD8+T cells. The two-independent-samples t test or the paired t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the Spearman correlation analysis was performed to investigate correlation. Results Compared with the health controls, the patients with ACLF had a significant increase in the serum level of IL-35 [72. 32 ( 54. 04-111. 30) pg/ml vs 46. 00 ( 27. 02-82. 29) pg/ml, Z = 2. 184, P = 0. 020]. CD8+T cell exhaustion was observed in ACLF patients, with the manifestations of reductions in the relative mRNA expression of perforin and granzyme B, increases in the percentages of PD-1+or CTLA-4+CD8+T cells, and reductions in the cytolytic ( induction of target cell death) and noncytolytic ( secretion of interferon-γ) functions of CD8+T cells ( all P < 0. 05) . After the stimulation with recombinant IL-35, both ACLF patients and healthy controls had significant reductions in the relative mRNA expression of perforin and granzyme B in CD8+T cells, significant increases in the percentages of PD-1+orCTLA-4+CD8+T cells, and significant reductions in the cytolytic and noncytolytic functions of CD8+T cells ( all P < 0. 05) . Conclusion Elevated IL-35 can suppress the cytolytic activity of CD8+T cells in ACLF patients, suggesting that IL-35 might induce the exhaustion of cellular immune function in ACLF patients.
[1] HAN Y, CUI LN, GUO GY. Immunotherapy for acute-onchronic liver failure[J]. J Clin Hepatol, 2017, 33 (9) :1677-1682. (in Chinese) 韩英, 崔丽娜, 郭冠亚.慢加急性肝衰竭的免疫治疗[J].临床肝胆病杂志, 2017, 33 (9) :1677-1682.
|
[2] TEYMOURI M, PIRRO M, FALLARINO F, et al. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases[J]. Int J Cancer, 2018, 143 (9) :2105-2115.
|
[3] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018) [J]. J Clin Hepatol, 2019, 35 (1) :38-44. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2018年版) [J].临床肝胆病杂志, 2019, 35 (1) :38-44.
|
[4] LI Y, ZHANG H, LI Z, et al. Influence of the Notch signaling pathway on CD8+T lymphocyte function in patients with chronic hepatitis C[J]. J Clin Hepatol, 2018, 34 (2) :287-291. (in Chinese) 李彧, 张鸿, 李竹, 等. Notch信号通路对慢性丙型肝炎患者CD8+T淋巴细胞功能的影响[J].临床肝胆病杂志, 2018, 34 (2) :287-291.
|
[5] WANG HM, ZHANG XH, FENG MM, et al. Interleukin-35suppresses the antitumor activity of T cells in patients with non-small cell lung cancer[J]. Cell Physiol Biochem, 2018, 47 (6) :2407-2419.
|
[6] ZHANG J, ZHANG Y, WANG Q, et al. Interleukin-35 in immune-related diseases:Protection or destruction[J]. Immunology, 2019, 157 (1) :13-20.
|
[7] DAMO M, JOSHI NS. Treg cell IL-10 and IL-35 exhaust CD8+T cells in tumors[J]. Nat Immunol, 2019, 20 (6) :674-675.
|
[8] TENG DK, LIU Y, LV YF, et al. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection[J]. Int Immunopharmacol, 2019, 70:252-259.
|
[9] SHAO X, MA J, JIA S, et al. Interleukin-35 suppresses antiviral immune response in chronic hepatitis B virus infection[J]. Front Cell Infect Microbiol, 2017, 7:472.
|
[10] LIU S, ZHANG Q, SHAO X, et al. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection[J]. Int Immunopharmacol, 2017, 50:87-94.
|
[11] FU YP, YI Y, CAI XY, et al. Overexpression of interleukin-35associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection[J]. Br J Cancer, 2016, 114 (7) :767-776.
|
[12] CHEN L, LUO EP, HUANG XP, et al. Expression of IL-35 in patients with acute-on-chronic liver failure and its clinical significances[J]. J Practical Med, 2013, 29 (17) :2800-2802. (in Chinese) 陈丽, 罗二平, 黄小平, 等.乙型慢加亚急性肝衰竭患者血清白细胞介素-35的表达及其临床意义[J].实用医学杂志, 2013, 29 (17) :2800-2802.
|
[13] DURGEAU A, VIRK Y, CORGNAC S, et al. Recent advances in targeting CD8 T-Cell immunity for more effective cancer immunotherapy[J]. Front Immunol, 2018, 9:14.
|
[14] LIU MX, LIU QY, LIU Y, et al. Interleukin-35 suppresses antitumor activity of circulating CD8+T cells in osteosarcoma patients[J]. Connect Tissue Res, 2019, 60 (4) :367-375.
|
[15] ZHENG XF, HU XY, FANG H, et al. Interleukin-35 attenuates D-galactosamine/lipopolysaccharide-induced liver injury via enhancing interleukin-10 production in Kupffer cells[J].Front Pharmacol, 2018, 9:959.
|
[16] WANG W, GUO H, LI H, et al. Interleukin-35 gene-modified mesenchymal stem cells protect concanavalin a-induced fulminant hepatitis by decreasing the interferon gamma level[J]. Hum Gene Ther, 2018, 29 (2) :234-241.
|